代谢组学和肾癌中代谢重编程的研究进展  

Progress in metabonomics and metabolic reprogramming in renal cell carcinoma

作　　者：来嘉伟 程永毅[1] 周建成[1] LAI Jiawei;CHENG Yongyi;ZHOU Jiancheng(Department of Urology,Shaanxi Provincial People’s Hospital,Shaanxi Xi'an 710068,China;Medical School of Yan'an University,Shaanxi Yan'an 716000,China)

机构地区：[1]陕西省人民医院泌尿外科,陕西西安710068 [2]延安大学医学院,陕西延安716000

出　　处：《现代肿瘤医学》2022年第17期3217-3220,共4页Journal of Modern Oncology

基　　金：陕西省自然科学基金面上项目(编号:2020JM-657)。

摘　　要：肾细胞癌是泌尿系统常见的疾病,其癌组织中包括VHL、mT OR等代谢基因突变,这促使人们利用高通量技术来测量小分子代谢物(即代谢组学)。对肾透明细胞癌(clear cell renal cell carcinoma,ccRCC)的研究中,已经发现了由控制肿瘤能量学和生物合成的相同基因所介导的代谢途径的变化,这种经典的生化途径对肿瘤的生存优势被称为代谢重编程,从而出现了ccRCC是一种代谢性疾病的概念。本文将提供代谢组学技术的一般概述并对肾透明细胞癌相关代谢重编程研究进展作一综述。Renal cell carcinoma(RCC)is a commonurogenital disorder.Its histologies appear mutation of metabolic genes,including VHL,MTOR.This has prompted researcher to measure small-molecule metabolites by leveraging high-throughput technologies(i.e.,metabolomics).In a study of clear cell renal cell carcinoma(ccRCC),ccRCC has uncovered changes in metabolic pathways mediated by those same genes that control tumor energetics and biosynthesis.This adaptation of classic biochemical pathways to the tumor’s advantage has been labeled metabolic reprogramming.So the concept that ccRCC is a metabolic disease has emerged.This review provides a general overview of the technique of metabolomics and recent advances in metabolomics in ccRCC.

关 键 词：代谢组学 肾癌 肾透明细胞癌 代谢重编程 

分 类 号：R737.11[医药卫生—肿瘤]